Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103)

22-Oct-2008 - USA

Elan Corporation, plc and Transition Therapeutics Inc. announced the achievement of the patient enrollment target for a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in patients with mild to moderate Alzheimer's disease. Each patient's planned treatment period is approximately 18 months.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance